Commitment to Patient-Centered Care
"I am passionate about providing the best, most advanced, cost-effective and compassionate care and education for my patients and their families; we make the decisions together as a team. We are lucky to have access to unique and advanced testing methods at HCMC such as EMG, ultrasound, MR imaging, autonomics, antibody testing, and biopsy. We also have advanced treatments such as infusions, pharmaceuticals, research trials and pharmaceuticals to offer. My team is here to offer this as necessary."
Dr. Guliani graduated from Vanderbilt University in Nashville, TN with a degree in Integrative Neurosciences. He attended medical school at the University of Illinois at Chicago, where he won a scholarship in his last year for neurology. He completed a residency in Neurology at the University of Minnesota; during his final year, he served as administrative chief resident. After fellowship training in Neuromuscular Medicine and electromyography at Washington University in Saint Louis, he returned to the Twin Cities.
He serves as Interim Assistant Chief of Neurology, Neuromuscular Division Director, EMG Lab Medical Director, and Site Director of the Neurology Residency, Clinical Neurophysiology Fellowship and Neuromuscular Medicine Fellowship.
Dr. Guliani is an Assistant Professor at the University of Minnesota Department of Neurology, where he serves as Assistant Residency Program Director.
Dr. Guliani specializes in nerve and muscle diseases, myasthenia gravis, immune diseases of the nervous system, ALS and motor neuron diseases, headache, nerve pain, and brachial plexopathies.
Dr. Guliani is involved in ALS and Multiple Sclerosis trials through the Minneapolis Medical Research Foundation, Northeast ALS Consortium, Western ALS Consortium, and the University of Minnesota. He is board certified in Neurology and Neuromuscular Medicine.
"Outside of work, I enjoy spending time with my family, music, hiking and sports."
- ADHERE trial: Medication Event Monitoring System (MEMS) to improve adherence to Tecfidera (delayed release dimethyl fumarate treatment) in MS (multiple sclerosis) (109MS413)
- A Multicenter Validation Study of the ALS Specific Quality of Life – Short Form Instrument (ALSSQOLR-SF)
- AVP-923: The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS) (Protocol NCT01806857)
- A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS) (Protocol # CY 4026)
- Cheong, I, Marjanska M, Lenglet, C, Rolandelli S, Guliani GK, Oz, G, Walk D. High and Ultra-High Field MR Spectroscopy in ALS. 25th International Symposium on ALS/MND. Brussels, Belgium. 6 Dec 2014.
- Guliani GK, Parry G. Multiple Sclerosis triggered by purified chick embryo cell rabies vaccine. Scientific Committee for the 5th Joint triennial congress of the European and Americas committees for treatment and research in multiple sclerosis. 15 Jul 2011: A780.
- Fiol-Elias M, Qureshi MH, Guliani GK, Adejoro OO, Hunt MA. Epilepsy in Gliomas. Neurology. 2011; 86: P03.157.
- Farrag A,Irfan M, Guliani GK, Tariq N, Taylor RA, Suri MF, Qureshi AI. Occurrence of post-acute recanalization and collateral formation in patients with cerebral venous and sinus thrombosis. A serial venographic study. Neurocritical Care.2010 Dec; 13(3):373-9.
University of Illinois, Chicago, IL, USA
Neurology, University of Minnesota, Minneapolis, MN, USA
Neuromuscular Medicine / EMG, Washington University/Barnes Jewish Hospital, St. Louis, MO, USA